-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Maintains Overweight on Cogent Biosciences, Raises Price Target to $55

Benzinga·08/17/2026 16:08:30
Listen to the news
Piper Sandler analyst Christopher Raymond maintains Cogent Biosciences (NASDAQ:COGT) with a Overweight and raises the price target from $52 to $55.